WANG, I JONG,王一中,王一中,HO, WEI TING,何威廷,何威廷,CHIANG, TING HSUAN,江亭萱,江亭萱,LIN, I TSEN,林奕岑,林奕岑
申请号：
TW102117942
公开号：
TW201408280A
申请日:
2013.05.21
申请国别(地区):
TW
年份:
2014
代理人:
摘要：
The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.本發明係關於一種以斑馬魚近視實驗篩選治療及/或預防近視及錐狀角膜疾病之候選藥物之平台。本發明主要係以透明蛋白(Lumican)、數種富含白氨基酸小多醣蛋白家族(small leucine-rich proteoglycan,SLRP)之一為基礎,其係於膠原纖維生成或影響斑馬魚眼球軸長之基因之調控上扮演重要角色,另外,亦於臨床近視上扮演重要角色。據此,本發明係採用所建立之斑馬魚近視實驗模組,進一步鑑定影響透明蛋白及膠原蛋白原纖維生成之表現之藥物、及/或影響眼球軸長及/或錐狀角膜疾病之調控之藥物。該等藥物係治療近視及/或錐狀角膜疾病之具潛力之候選藥物。
